Search Results
Jun 09, 2026, 11:00 ET From Creator Seeding to Retail Velocity in 18 Months: 5W Releases the CPG Creator Seeding Playbook 2026
beauty, supplements, pet products, baby and parent, home and housewares, alcohol, and emerging categories including functional beverage, GLP-1-aligned nutrition, and alt-protein. The Playbook includes deal-by-deal economics for each tier and the buyer-by-buyer briefing protocol for the top
More news about: 5W Public Relations
Jun 09, 2026, 10:08 ET Pogo Launches World's First AI Research Platform Powered by Purchase-Verified Buyers; Announces $32M Raised to Date
why some ride again - and why others churn after their first rideA Fortune 500 food manufacturer built a data-backed multi-year view of how GLP-1s are changing what people buyA leading investor used Pogo to identify paying Gen Z subscribers of an AI tool as part of investment due diligenceAs
More news about: Pogo Technologies
Jun 09, 2026, 10:01 ET Alcohol-associated Liver Disease Market Gearing Up for Outstanding Expansion at a CAGR of 31.1% During the Forecast Period (2026-2036) | DelveInsight
GLP-1 Agonists MarketGLP-1 Agonists Market Size, Target Population, Competitive Landscape & Market Forecast – 2036 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key GLP-1 agonists
More news about: DelveInsight Business Research, LLP
Jun 09, 2026, 09:52 ET New Skytale Market Intelligence Report Explores the Future of Longevity, GLP-1s, and Personalized Care
New report explores the convergence of preventive healthcare, personalized medicine, GLP-1s, concierge care, and healthcare value creationDALLAS, June 9, 2026 /PRNewswire/ -- Skytale Group ("Skytale"),
More news about: Skytale Group
Jun 09, 2026, 09:10 ET Parker Waichman LLP Files Lawsuit on behalf of Massachusetts Resident Alleging Development of Irreversible Eye Condition, NAION, after taking Wegovy
Waichman continues to file additional cases and urges individuals who have suffered serious eye injuries after taking these widely prescribed GLP-1 receptor agonist medications to contact them for a
More news about: Parker Waichman LLP
Jun 09, 2026, 09:00 ET SmithRx Launches Best-in-Class Partner Ecosystem to Help Employers Deliver Sustainable and Clinically Appropriate GLP-1 Programs at Scale
formulary selection. While most employers that currently cover GLP-1s for weight management expect to maintain coverage next year, a meaningful portion are uncertain or anticipate halting coverage altogether. Employers who do not yet cover GLP-1s for weight management are signaling that it's unlikely they
More news about: SmithRx
Jun 09, 2026, 08:34 ET PEPPER Introduces the Muscle Activation Suit Built to Make Strength Training Smarter and More Accessible
of long-term health, spanning metabolic function, bone density, balance, and injury prevention. For the growing number of Americans using GLP-1 medications, maintaining muscle during weight loss has become a clinical priority."Traditional strength training remains out of reach for
More news about: PEPPER
Jun 09, 2026, 08:00 ET Nambawan Spain Launches Thaûma™, a Breakthrough Natural Sweetener Designed to Transform Sugar Reduction in Food and Beverage Products
in 2024 to more than $15 billion by 2033, driven by increasing demand for healthier, lower-calorie alternatives to sugar. At the same time, GLP-1 adoption is accelerating demand for better-tasting, nutrient-conscious food and beverage products.Thaûma™ is a non-caloric, non-glycemic,
More news about: Nambawan
Jun 09, 2026, 08:00 ET DiMe convenes payers and virtual-first care providers to close the operational gap that leaves contracted virtual care providers invisible to patients
model combines human-led care teams, connected devices, and AI-enabled technology to deliver personalized care at scale, including support for GLP-1 therapy. Omada has served more than two million members since launch across 2,000+ employers, health plans, pharmacy benefit managers, and health
More news about: Digital Medicine Society (DiMe)
Jun 09, 2026, 07:00 ET RedHill's Opaganib Receives FDA Rare Pediatric Disease Designation for Neuroblastoma in Addition to Current Orphan Drug Designation
prostate cancer in combination with Bayer's darolutamide; (ii) RHB-102 (Bekinda®), with a planned Phase 2 proof-of-concept study for GLP-1/GIP receptor agonist-associated GI intolerance, positive results from a U.S. Phase 3 study for acute gastroenteritis and gastritis, positive results
More news about: RedHill Biopharma Ltd.
Jun 09, 2026, 05:13 ET Whole-Body Spatial Intelligence Beyond Weight-loss: nference Advances Cardiometabolism Moat for Precision Peptide Medicines and Healthy Longevity
Compounded GLP-1 UseIn the study "Auditable LLM curation of clinical notes refines GLP-1 initiation, persistence ascertainment and compounding use beyond prescription records," the MAIA team exposed a central vulnerability in GLP-1 real-world evidence:
More news about: nference
Jun 09, 2026, 00:01 ET More Than Half of Europeans Are Worried About Their Personal Finances, Driving Spending Cutbacks
pet food, and 68% want clearly recognizable ingredients listed on labels.Nearly three-quarters (74%) of Europeans now recognize GLP-1 appetite-suppressing medications, and one in four report either using them or seriously considering doing so.Digital Channels
More news about: Boston Consulting Group (BCG)
Jun 08, 2026, 20:00 ET 沃特世率先推出反相生物分離層析柱，GLP-1表徵速度提升高達3倍、LNP組分分析提速2倍
+與C18+兩種化學填料，採用230 Å孔徑顆粒，旨在支持高效的傳質過程，確保在U(H)PLC及HPLC系統中的性能一致性，並在從早期研發到商業化生產的全過程中提供可靠的批次檢測結果。GLP-1胜肽類的分析難度極高，因為許多雜質僅相差一個原子，甚至有些雜質原子組成完全相同，只在空間排列上有所差異。BioResolve胜肽苯己基+與C18+層析柱專為分離此類頑固雜質而構建，並提供300 mm規格的特殊柱長，以滿足更大分離性能需求及更深度的雜質表徵。Alembic Pharmaceuticals集團負責人Ashish Kanhed評價道：「BioResolve胜肽反相層
More news about: Waters Corporation
Jun 08, 2026, 16:15 ET Novel Once-Daily Pill Delivers Positive Blood Glucose and Weight Reduction Results
diabetes now use injectable GLP-1 RAs — a class of medications that mimic the naturally occurring GLP-1 hormone – to help lower blood glucose levels and support weight loss. There is a growing need to expand oral formulations of GLP-1 RAs to expand treatment options
More news about: American Diabetes Association
Jun 08, 2026, 14:30 ET ACHIEVE Trials Demonstrate Comparative Benefits of Novel, Small-Molecule Oral GLP-1 RA, Expanding Oral Treatment Options for Patient Population in Need of Alternative Solutions
using injectable GLP-1 RA therapies, creating an unmet need for effective oral options.Orforglipron is an investigational once-daily pill designed to help adults with type 2 diabetes lower blood glucose levels and support weight loss by mimicking GLP-1, a natural hormone involved
More news about: American Diabetes Association
Jun 08, 2026, 14:30 ET Lilly's oral GLP-1 Foundayo (orforglipron) delivered superior A1C control and weight loss in three pivotal type 2 diabetes trials
shift toward using oral GLP-1 receptor agonist therapies like orforglipron earlier as a foundation of type 2 diabetes care."In ACHIEVE-3, Foundayo 9 mg and 17.2 mg outperformed oral semaglutide 7 mg and 14 mg in the first and only head-to-head Phase 3 trial of two oral GLP-1 receptor agonists for
More news about: Eli Lilly and Company
Jun 08, 2026, 14:12 ET AG1 LAUNCHES AG1 PRO WITH CREATINE AND MORE FOR ADVANCED MUSCLE AND GUT SUPPORT
modern consumer, who has a greater nutritional awareness and increased demand for muscle and gut health support. With millions of people incorporating GLP-1s into their health routines, those demands are growing rapidly. AG1 Pro delivers targeted muscle support and gut optimization in a single serving,
More news about: AG1
Jun 08, 2026, 10:01 ET 2026 Protein Market Report: Whey Supply Crisis, FMCG-Led Growth Surge, and Ingredient Import Disruptions Reshape the $133 Billion Industry
brands.GLP-1 Diet Protein Is Creating a New Nutrition MarketGLP-1 diet protein market is valued at USD 3.1B in 2026 and projected to reach USD 15.4B by 2036 (17.4% CAGR). Driven by rapid adoption of GLP-1 drugs like semaglutide and tirzepatide
More news about: Market Decipher
Jun 08, 2026, 10:01 ET CRISP POWER Protein Pretzels Opens $15M Texas Production Facility, Doubling Down on U.S. Expansion
sugar management, and macronutrient balance is driving demand for snacks that deliver real nutrition in familiar formats, and the rise of GLP-1 medications has amplified that shift, increasing interest in options that provide substance and sustained fullness. CRISP POWER's high-protein,
More news about: CRISP POWER
Jun 08, 2026, 08:31 ET MetaVia Presents New Late-Breaking Obesity and Metabolic Data at the ADA 2026 Scientific Sessions Supporting DA-1726 Differentiation and Vanoglipel Combination Potential
a novel GLP1R/GCGR dual agonist for the treatment of obesity and Metabolic Dysfunction-Associated Steatohepatitis (MASH) that is to be administered once weekly subcutaneously. DA-1726 acts as a dual agonist of GLP-1 receptors
More news about: MetaVia Inc.
Jun 08, 2026, 08:00 ET Waters Launches Industry-First Reversed-Phase Bioseparation Columns to Deliver Up to 3x Faster GLP-1 Characterization and 2x Faster LNP Component Analysis
Faster run times for GLP-1, insulin, and LNP drug substance testing accelerates biopharmaceutical development timelines and reduces production bottlenecks.Delivers up to 2x increase in resolving power and sensitivity to identify and track low-level impurities for improved
More news about: Waters Corporation
Jun 08, 2026, 08:00 ET Waters Launches Industry-First Reversed-Phase Bioseparation Columns to Deliver Up to 3x Faster GLP-1 Characterization and 2x Faster LNP Component Analysis
Faster run times for GLP-1, insulin, and LNP drug substance testing accelerates biopharmaceutical development timelines and reduces production bottlenecks.Delivers up to 2x increase in resolving power and sensitivity to identify and track low-level impurities
More news about: Waters Corporation
Jun 08, 2026, 08:00 ET Dario Presents Four Studies at American Diabetes Association Scientific Sessions Highlighting Commercial and Clinical Value of its Digital Health Platform
plans, employers and other enterprise buyers Weight loss of 6.4% with Dario alone, and 14.3% when combined with a GLP-1 at 12 months, exceeding benchmarks based on medications alone44.8% of high-risk diabetes users achieved at least a
More news about: DarioHealth Corp.
Jun 08, 2026, 08:00 ET Vasa Therapeutics to Deliver Two Presentations on VS-041 at ECM2026, Featuring Preclinical and First-in-Human Data and Ongoing Phase 1c Trial Design in HFpEF
and significantly improved diastolic heart function. The compound also inhibits the release of endotrophin from primary human cardiac fibroblasts. In GLP toxicology studies, VS-041 demonstrated a highly favorable safety and tolerability profile. This clean safety profile was successfully translated to
More news about: Vasa Therapeutics
Jun 08, 2026, 07:00 ET RedHill Launches Enforcement of $11 Million New York Supreme Court Final Judgment Against Kukbo
prostate cancer in combination with Bayer's darolutamide; (ii) RHB-102 (Bekinda®), with a planned Phase 2 proof-of-concept study for GLP-1/GIP receptor agonist-associated GI intolerance, positive results from a U.S. Phase 3 study for acute gastroenteritis and gastritis, positive results
More news about: RedHill Biopharma Ltd.